In 1957, Sjögren and Larsson described a cohort of Swedish patients with an unusual combination of symptoms that included of congenital ichthyosis, intellectual disability, and spastic diplegia or tetraplegia.  Family studies indicated that Sjögren-Larsson syndrome (SLS) was a genetic disorder with autosomal recessive inheritance. Similar patients of all ethnic origins were subsequently recognized throughout the world. 
Two decades later, Sjögren-Larsson syndrome was shown to be an inborn error of lipid metabolism caused by deficient activity of fatty alcohol:NAD oxidoreductase.  Subsequent studies identified a defect in fatty aldehyde dehydrogenase (FALDH), a component of the fatty alcohol:NAD oxidoreductase enzyme complex.  The FALDH gene (renamed ALDH3A2) was cloned in 1996, and patients with Sjögren-Larsson syndrome were found to have mutations in this gene. [5, 6] Enzymatic and genetic testing provide a reliable means for diagnosing Sjögren-Larsson syndrome and determining carrier status.  Sjögren-Larsson syndrome is now the most widely recognized form of neuroichthyosis
The genetic defect in Sjögren-Larsson syndrome results in deficient activity of FALDH, which catalyzes the oxidation of fatty aldehyde to fatty acid. New insight into the pathogenesis of Sjögren-Larsson syndrome is emerging from knowledge about the metabolic role of this enzyme.  FALDH acts on fatty aldehydes derived from metabolism of fatty alcohol,  phytanic acid (a branched-chain fatty acid),  phytol (the alcohol precursor to phytanic acid),  ether glycerolipids,  and leukotriene B4.  Tissue dysfunction is thought to be due to lipid storage in membranes.  FALDH is a component of the fatty alcohol:NAD oxidoreductase enzyme complex that catalyzes the sequential oxidation of fatty alcohol to aldehyde and fatty acid. Therefore, patients with Sjögren-Larsson syndrome have deficient activity of FALDH and fatty alcohol:NAD oxidoreductase, which results in defective metabolism of both fatty aldehyde and fatty alcohol. 
In Sjögren-Larsson syndrome , FALDH deficiency impairs fatty alcohol oxidation and leads to accumulation of 16- and 18-carbon-long aliphatic alcohols.  In cultured skin keratinocytes, elevated fatty alcohol is diverted into the synthesis of wax esters and alkyldiacylglycerol lipids.  Accumulation of fatty alcohol and related lipid products disrupts formation of the intercellular membranes in the stratum corneum, which is critical for epidermal water barrier.  The skin attempts to reestablish a water barrier by making more stratum corneum, resulting in ichthyosis.
Fatty alcohol and aldehyde may likewise alter the normal integrity of myelin membranes in the brain, leading to white-matter disease and spasticity.  FALDH is involved in the oxidation of fatty aldehydes produced by catabolism of ether glycerolipids (plasmalogens), which are prominent phospholipids in myelin. Accumulation of fatty aldehydes, which are highly reactive molecules, can form covalent Schiff-base derivatives with phosphatidylethanolamine, which may influence myelin membrane properties and alter the function of membrane-bound proteins.  Schiff-base aldehyde adducts with other amino-containing molecules, including key membrane enzymes and proteins, may also be detrimental to their function.
Patients with Sjögren-Larsson syndrome accumulate leukotriene B4 and its omega-hydroxy metabolite, which are probably responsible for the pruritus seen in this disease.  Furthermore, patients with this disorder have low levels of certain polyunsaturated fatty acids in plasma, which can contribute to the cutaneous and neurologic disease in Sjögren-Larsson syndrome.
The macular degeneration in Sjögren-Larsson syndrome is associated with fundal autofluorescence and a unique deficiency of retinal macular pigments, especially the carotinoid zeaxanthin.  This may reflect increased photo-oxidation and cellular toxicity with lipofuscin deposition in the retina.
The incidence is not known.
The prevalence is estimated to be 0.4 cases per 100,000 people in Sweden.  The prevalence elsewhere is not known.
Patients with Sjögren-Larsson syndrome usually survive well into adulthood. Life expectancy of those with Sjögren-Larsson syndrome is probably determined by the severity of neurologic symptoms and is comparable to that of other patients with static or slowly progressive neurologic disease. Morbidity is associated with chronic neurologic disease and lifelong ichthyosis.
Sjögren-Larsson syndrome has been diagnosed in patients of all races.
Sjögren-Larsson syndrome is autosomal recessive. Male and female individuals are equally affected.
Sjögren-Larsson syndrome is a genetic disease present from conception. Fetuses with Sjögren-Larsson syndrome have histologic evidence of ichthyosis as early as the end of the second trimester. Most infants with Sjögren-Larsson syndrome have cutaneous signs at birth; neurologic symptoms usually develop within 2 years. Symptoms persist throughout life.
What would you like to print?